Royal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE - Get Free Report)'s stock had its "sector perform" rating reissued by investment analysts at Royal Bank of Canada in a research report issued on Friday,Benzinga reports. They presently have a $4.00 target price on the biotechnology company's stock.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. lowered shares of bluebird bio from a "neutral" rating to an "underweight" rating in a report on Friday. StockNews.com started coverage on bluebird bio in a report on Sunday, November 10th. They issued a "sell" rating on the stock. Robert W. Baird lowered their target price on bluebird bio from $7.00 to $6.00 and set an "outperform" rating for the company in a report on Thursday, August 15th. Wells Fargo & Company reduced their target price on bluebird bio from $3.00 to $2.00 and set an "equal weight" rating for the company in a report on Wednesday, September 25th. Finally, Bank of America cut shares of bluebird bio from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $3.00 to $0.50 in a report on Friday. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $3.03.

bluebird bio Stock Down 11.4 %

Shares of BLUE traded down $0.04 during midday trading on Friday, reaching $0.32. 6,895,475 shares of the company were exchanged, compared to its average volume of 7,427,930. bluebird bio has a 1-year low of $0.32 and a 1-year high of $5.53. The company has a current ratio of 0.68, a quick ratio of 0.57 and a debt-to-equity ratio of 0.37. The company has a market cap of $62.26 million, a price-to-earnings ratio of -0.14 and a beta of 0.76. The stock has a 50-day moving average price of $0.49 and a 200-day moving average price of $0.79.

bluebird bio (NASDAQ:BLUE - Get Free Report) last posted its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. The business had revenue of $18.57 million for the quarter. Research analysts expect that bluebird bio will post -1.41 earnings per share for the current year.

Institutional Investors Weigh In On bluebird bio

A number of hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in bluebird bio by 38.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company's stock worth $416,000 after buying an additional 90,139 shares in the last quarter. Vanguard Group Inc. grew its holdings in bluebird bio by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company's stock worth $13,438,000 after acquiring an additional 1,723,081 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock worth $71,000 after purchasing an additional 29,113 shares during the last quarter. American International Group Inc. grew its stake in bluebird bio by 77.4% during the 1st quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company's stock valued at $121,000 after purchasing an additional 41,177 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in bluebird bio by 315.3% in the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company's stock valued at $1,223,000 after buying an additional 1,013,144 shares in the last quarter. 87.43% of the stock is currently owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.